September 4, 2024

Supplementary Figure S1 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Supplementary Figure S1 shows the EHMT-inhibition mediated loss of H3K9Me2 in the different HGSC models. It also shows the transcriptional changes via volcano plot and pathway analysis due to the treatment of single treatments and combination treatments.

Me gusta

Guardar

Cite This Study

Nguyen et al. (Wed,) studied this question.

synapsesocial.com/papers/68e5956cb6db643587530c2c https://doi.org/https://doi.org/10.1158/1535-7163.26935064

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024
2Supplementary Figure S6 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024
3Supplementary Figure S6 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024
4Supplementary Figure S5 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024
5Supplementary Figure S5 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation2024

Me gusta

Guardar